Intuitive Surgical dominates the robotic surgery market with its da Vinci system, increasing global procedures by 17% YoY. Revenue grew 21% to $2.44 billion in Q2, with systems revenue up 28%. The company plans to launch da Vinci 5 globally, with a healthy balance sheet and strong cash reserves of $9.5 billion.

Intuitive holds 60% of the global robotic surgery market and has installed over 11,000 da Vinci systems worldwide. Competitors like Medtronic, Johnson & Johnson, and Stryker have failed to gain market share due to the high cost and risk of switching platforms. Intuitive’s moat is unbreakable due to surgeon loyalty and high investments.

Despite its premium valuation, ISRG stock is rated a “Moderate Buy” on Wall Street. Analysts see a 21% upside potential with a target price of $602.96. Risk-averse investors can start accumulating shares around $400 to invest with a margin of safety in the growing robotic surgery market.

Read more at Yahoo Finance: One Buy-Rated Stock With an Unbreakable Moat That You Can’t Ignore